EP1883648A1 - Verfahren zur herstellung von reinem kristallinen tibolon - Google Patents
Verfahren zur herstellung von reinem kristallinen tibolonInfo
- Publication number
- EP1883648A1 EP1883648A1 EP05745217A EP05745217A EP1883648A1 EP 1883648 A1 EP1883648 A1 EP 1883648A1 EP 05745217 A EP05745217 A EP 05745217A EP 05745217 A EP05745217 A EP 05745217A EP 1883648 A1 EP1883648 A1 EP 1883648A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tibolone
- process according
- water
- crystals
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
- C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
- C07J1/0096—Alkynyl derivatives
Definitions
- the present invention provides a process for the preparation of Tibolone crystalline forms I and II characterised by high purity and low particle size.
- Tibolone The compound (7 ⁇ ,17 ⁇ )-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)- en-20-yn-3-one, known as Tibolone, is a steroid drug having combined estrogenic, progestagenic and androgenic characteristics, and is described in US patents Nos. 3340279 and 4701450. Tibolone is known to crystallize in two different polymorphic forms conventionally known as form I and form II. Form I, which proved more stable in pharmaceutical compositions, is preferably used in the production of tablets.
- EP389035 discloses a method of preparing crystalline pure Tibolone for use in a pharmaceutical composition, characterized in that the polymorphous compound is crystallized from mixtures of water and acetone or ethanol, or from ethyl acetate, acetonitrile, or acetone-hexane mixtures, or from an apolar solvent.
- the process disclosed in EP389035 allows the production of Form I with crystalline purity higher than 95%.
- the crystallisation of Tibolone using mixtures of methanol and water yields only mixtures of the two crystalline forms.
- the invention provides a process for preparing pure crystalline forms of the compound (7 ⁇ ,17 ⁇ )-17-hydroxy-7-methyl-19-nor-17-pregn- 5(10)-en-20-yn-3-one (Tibolone), which essentially comprises the steps of:
- step (d) washing the crystals with water.
- the organic bases used in steps (a) and (b), which can be the same or different, are preferably selected from aliphatic or aromatic (tertiary) amines, such as triethylamine and pyridine.
- the ratio between the amine and methanol or water, according to steps (a) and (b), respectively, can vary from 1 :600 to 1 :50 by volume.
- methanol and water are used in respective amounts ranging from 2: 1 to 1 :2 by volume, more preferably 1 : 1.
- the dissolution of Tibolone in methanol, according to step (a), is generally carried out by heating a suspension of the compound to a temperature of 35 ⁇ 45°C, preferably 38 ⁇ 42°C, under constant stirring.
- Pouring of the methanol solution into water according to step (b) is carried out in a time sufficient for the crystals to form, depending on the solution volumes and the equipment/apparatus utilized, generally variable between 30 and 60 min, preferably between 40 and 50 min.
- the crystallization process can be selectively oriented to the production of pure crystalline forms I or II by simply varying the temperature of the water solution used in step (b).
- the water solution of step (b) at temperatures ranging from 40 to 5O 0 C and from -5 to +5°C, highly pure crystalline forms I and II can be obtained, respectively.
- Preferred temperatures ranges are 43 ⁇ 47°C and -5 ⁇ 0°C, for crystalline forms I and II, respectively.
- the filtration and the washing steps (c) and (d) are preferably perfomed at the same temperature used in the crystallization step (b).
- wet crystalline Tibolone is dried, preferably at temperatures of 20 ⁇ 50°C for a time that can vary from few hours to some days.
- the product thus obtained is characterised by a high crystalline purity. Moreover when the 100% of the resulting particle size distribution is below 40 ⁇ m, the obtained Tibolone could be considered particularly suitable for direct use in the preparation of solid pharmaceutical compositions, without prior micronization.
- Polymorphic Tibolone (60.00 g) is suspended in 720 ml of CH 3 OH/Py solution and stirred at 27°C for 10'. The slurry is heated at 40 0 C and stirred until dissolution occurs. Tibolone solution is filtered and washed with 180 ml of CH 3 OH/Py and thermostated at 40 0 C.
- the H 2 O/Py mixture is filtered and thermostated at 45°C.
- the methanolic solution containing Tibolone is added over a period of 42' over the H 2 O/Py solution constantly kept under nitrogen atmosphere. During the addition the temperature of H 2 O/Py is 45°C. At the end of the addition the crystallized Tibolone is allowed to stir for 5', then filtered when the temperature is 42°C. The cake is washed with water and the product dried in a static dryer for 60 hours at 35°C. 57.0 g of Tibolone are obtained with the following characteristics:
- Tibolone Dimethoxy Ketal are hydrolyzed in mild acidic conditions, following one of the suitable procedures well known to the person skilled in the art, thus obtaining 36.0 g of wet Tibolone.
- the humid polymorphous product is dissolved in CH 3 OH/Py (230.4 ml) at 40 0 C, the solution is filtered, washed with CH 3 OH/Py (57.6 ml) and constantly kept at a temperature of 40 0 C.
- the methanolic solution is then gradually transferred on a H 2 O/Py (288 ml) solution over a period of 30' containing seed-crystals of Tibolone mixture F/Fn 90:10.
- n°2 is reported the solid state NMR spectrum in the region 210 ⁇ 220 ppm of EB2/TBL 0297.
- Crystal Seeds Mixture F 1 ZF n 85:15; Atmosphere: Conventional.
- Tibolone Dimethoxy Ketal are hydrolyzed in mild acidic conditions, following one of the suitable procedures well known to the person skilled in the art, thus obtaining 36.0 g of wet Tibolone.
- the humid polymorphous product is dissolved in CH 3 OHZPy (230.4 ml) at 40 0 C, the solution is filtered, washed with CH 3 OH/Py (57.6 ml) and constantly kept at a temperature of 40 0 C.
- the methanolic solution is then gradually transferred on a H 2 O/Py (288 ml) solution over a period of 30' containing seed-crystals of Tibolone mixture Fi/F ⁇ 85: 15.
- the crystallized Tibolone is allowed to stir for 5' before filtration. Crystals are washed with H 2 O, dried for 16 hours at a temperature of 35°C, thus yielding 18.44 g of dry Tibolone of the following quality:
- n°3 is reported the solid state NMR spectrum in the region 210 ⁇ 220 ppm of EB2/TBL 0298.
- Crystal Seeds Mixture F 1 ZF n 80:20; Atmosphere: Conventional.
- Tibolone Dimethoxy Ketal are hydrolyzed in mild acidic conditions, following one of the suitable procedures well known to the person skilled in the art, thus obtaining 36.0 g of wet Tibolone.
- the humid polymorphous product is dissolved in CH 3 OH/Py (230.4 ml) at 40 0 C, the solution is filtered, washed with CH 3 OH/Py (57.6 ml) and constantly kept at a temperature of 4O 0 C.
- the methanolic solution is then gradually transferred on a H 2 O/Py (288 ml) solution over a period of 30' containing seed-crystals of Tibolone mixture Fi/F ⁇ 80:20.
- the crystallized Tibolone is allowed to stir for 5' before filtration. Crystals are washed with H 2 O, dried for 16 hours at a temperature of 35°C, thus yielding 17.38 g of dry Tibolone of the following quality: HPLC purity > 99,0%
- n°4 is reported the solid state NMR spectrum in the region 210 ⁇ 220 ppm of EB2/TBL 0299.
- Tibolone Dimethoxy Ketal are hydrolyzed in mild acidic conditions, following one of the suitable procedures well known to the person skilled in the art, thus obtaining 131.0 g of wet Tibolone.
- the humid polymorphous product is dissolved in CH 3 OH/Py (806.3 ml) at 40 0 C, the solution is filtered, washed with CH 3 OH/Py (201.6 ml) and constantly kept at a temperature of 40 0 C. The methanolic solution is then gradually transferred, over a period of 30', on a H 2 O/Py (1000.0 ml) solution under slow stirring. The crystallized Tibolone is allowed to stir for 5' before filtration. Crystals are washed with H 2 O 5 dried for 16 hours at a temperature of 35°C, thus yielding 63.8 g of dry Tibolone of the following quality:
- n°6 is reported the solid state NMR spectrum in the region 210 ⁇ 220 ppm of EBl/TBL 203.
- Tibolone Dimethoxy Ketal 16.0 g are hydrolyzed in mild acidic conditions, following one of the suitable procedures well known to the person skilled in the art, thus obtaining 23.0 g of wet Tibolone.
- the humid polymorphous product is dissolved in CH 3 OH/Py (118.0 ml) at 40 0 C, the solution is filtered, washed with CH 3 OH/Py (16.0 ml) and constantly kept at a temperature of 40 0 C.
- the methanolic solution is then gradually transferred in a period of 15 minutes on a filtered and cooled mixture (-5/0 0 C) of H 2 O/Py (229.0 ml).
- the mixture is allowed to stir at 0/2 0 C for 10', before proceeding to crystals filtration and washing with water.
- the obtained product is dried for 12 hours at a temperature of 35°C, thus yielding 8.5 g of dry Tibolone of the following quality:
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2005/005560 WO2006125453A1 (en) | 2005-05-23 | 2005-05-23 | Process for the preparation of pure crystalline tibolone |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1883648A1 true EP1883648A1 (de) | 2008-02-06 |
Family
ID=35811772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05745217A Withdrawn EP1883648A1 (de) | 2005-05-23 | 2005-05-23 | Verfahren zur herstellung von reinem kristallinen tibolon |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1883648A1 (de) |
WO (1) | WO2006125453A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20130120A1 (it) * | 2013-01-25 | 2014-07-26 | Ind Chimica Srl | Processo per la preparazione in forma cristallina di tibolone, (7alfa,17alfa)-17-idrossi-7-metil-19-norpregn-5(10)-en-20-in-3-one |
CN114409717B (zh) * | 2021-12-17 | 2023-03-17 | 湖南科益新生物医药有限公司 | 替勃龙中间体醚化物和替勃龙的制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE63051B1 (en) * | 1989-03-18 | 1995-03-22 | Akzo Nv | Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one |
DE69907495T2 (de) * | 1998-10-16 | 2004-05-06 | Akzo Nobel N.V. | (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5-(10)-en-20-yn-3-on als reine verbindung |
-
2005
- 2005-05-23 EP EP05745217A patent/EP1883648A1/de not_active Withdrawn
- 2005-05-23 WO PCT/EP2005/005560 patent/WO2006125453A1/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO2006125453A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006125453A1 (en) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5400766B2 (ja) | ステビオシドの多形及び無定形形態、これらの配合方法、並びに使用法 | |
US6022985A (en) | Process for the preparation of 4-acetoxy-2α-benzoyloxy-5β, 20-epoxy-1, 7β-10β-trihydroxy-9-oxo-tax-11-en-13α-yl(2R,3S)-3-tert-b utoxy-carbonYlamino-2-hydroxy-3-phenylpropionate trihydrate | |
JP2019142882A (ja) | 結晶性ミノサイクリン塩基及びその製造方法 | |
JP2017061575A (ja) | 逆溶媒を使用する逆転写酵素阻害剤の結晶化方法 | |
JPH02191255A (ja) | トラセミドの安定な変態の製法 | |
EP1873158B1 (de) | Kristalle eines morphinanderivats und verfahren zu deren herstellung | |
JP6657269B2 (ja) | Pci―32765の結晶型aの調製方法 | |
CN108727334B (zh) | 一种甲磺酸达比加群酯的生产工艺 | |
IL101358A (en) | Tiagabine hydrochloride crystalline monohydrate, its preparation and pharmaceutical preparations containing the same | |
JPH09506601A (ja) | 結晶性n−アセチルノイラミン酸誘導体およびその製造法 | |
EP1883648A1 (de) | Verfahren zur herstellung von reinem kristallinen tibolon | |
JP2023510051A (ja) | 新規な結晶形形態のエドキサバン及びその製造方法 | |
JP4681545B2 (ja) | 血小板凝集阻害剤の結晶多形の製法 | |
US4219641A (en) | Process for preparing erythromycin succinate | |
EP2414378B1 (de) | Abtrennung der verbindung 4-azaandrost-1-en-17-carbonsäure von der verbindung 4-azaandrostan-17-carbonsäure | |
CN100408554C (zh) | 高纯度肼基碳酸甲酯的合成新工艺 | |
KR20090044694A (ko) | 모사프리드의 신규한 동질이상체 및 유사동질이상체 | |
JPH03240793A (ja) | アンフォテリシンbの精製方法および組成物 | |
EP1945623A2 (de) | Polymorphe von 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)-(methylsulfonyl)-amino]-n-methyl-1-benzofuran-3-carboxamid und verfahren zu ihrer herstellung | |
KR20230042322A (ko) | 빌란테롤 트리페나테이트의 정제 방법 | |
WO2005122698A2 (en) | Novel stable polymorphic forms of tiagabine hydrochloride | |
KR20010006117A (ko) | 단일 에난티오머 나웨딘을 제조하기 위한 방법 | |
JPS5885892A (ja) | 新規な結晶性3−セフエム−4−カルボン酸塩および精製法 | |
JP2008285446A (ja) | (±)2−(ジメチルアミノ)−1−{〔O−(m−メトキシフェネチル)フェノキシ〕メチル}エチル水素サクシナート塩酸塩のI形結晶とII形結晶の混晶の製造法 | |
CN117466914A (zh) | 一种巴洛沙韦酯新晶型及其用于产品纯化的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20071109 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20080530 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20141104 |